Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salmonella oral vaccine
- Development stage
- Unknown
- Lead developer
- Belarusian Research Center for Pediatric Oncology Hematology and Immunology
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Salmonella oral vaccine** is an experimental, personalized oral bacterial-vector DNA cancer vaccine being developed by the Belarusian Research Center for Pediatric Oncology, Hematology and Immunology for relapsed neuroblastoma. It uses attenuated *Salmonella enterica* serovar Typhimurium strain SS2017 carrying a plasmid DNA vaccine encoding a selected neuroblastoma-associated antigen fused to potato virus X coat protein as an immune enhancer. Candidate tumor antigens include tyrosine hydroxylase, paired-like homeobox 2B, survivin, melanoma-associated antigen 1, melanoma-associated antigen 3, and preferentially expressed antigen in melanoma. The oral product is administered as part of a combined vaccination strategy that also includes intramuscular administration of a DNA-polyethylenimine polyplex, with the objective of inducing cellular immune responses against antigen-expressing neuroblastoma cells.
- Other names
- attenuated Salmonella enterica serovar Typhimurium SS2017 DNA vaccine
02
Targets
PHOX2B (Paired-like homeobox 2b protein)BIRC5 (Survivin)TH (Tyrosine hydroxylase)
Beyond the preview
Go deeper on Salmonella oral vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Salmonella oral vaccine.